Compare SY & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | AARD |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.0M | 231.9M |
| IPO Year | 2019 | 2025 |
| Metric | SY | AARD |
|---|---|---|
| Price | $2.92 | $14.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $5.50 | ★ $30.63 |
| AVG Volume (30 Days) | ★ 962.2K | 219.1K |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,132,009.00 | N/A |
| Revenue This Year | $5.27 | N/A |
| Revenue Next Year | $51.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.67 | $4.88 |
| 52 Week High | $6.28 | $19.58 |
| Indicator | SY | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 41.24 | 65.38 |
| Support Level | $2.79 | $14.27 |
| Resistance Level | $3.33 | $16.00 |
| Average True Range (ATR) | 0.18 | 1.07 |
| MACD | 0.01 | 0.52 |
| Stochastic Oscillator | 23.15 | 79.91 |
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.